We use cookies to analyse how visitors use our website and to help us provide the best possible experience for users. View our Cookie Policy for more information. Cookies help us analyse how visitors use our website & provide the best user experience. View our Cookie Policy.
Nov 16

Advised the shareholders of Evaluate on an investment by HgCapital

Quayle Munro is pleased to announce that it has advised the shareholders of Evaluate Group Limited (“Evaluate”), a leading provider of commercial intelligence to the global life sciences industry, on an investment from HgCapital’s Mercury Fund (“HgCapital”) to support the Company’s strategic growth plans.

Evaluate is the trusted source for life science commercial intelligence and analysis with exclusive consensus forecasts to 2022. It has a range of online subscription services covering the Pharmaceutical, Biotech, and Medtech sectors. The Company also provides project-based analytical and data services and has an award-winning editorial team, EP Vantage. Evaluate supplies mission critical commercial information for complex business decisions to the pharmaceutical industry. Evaluate’s core product is an industry leading set of analyst consensus forecasts that provides detailed insights at the product, disease, indication and geographic level. Evaluate creates value by structuring, normalising and integrating data from company filings, research organisations, and government bodies and providing tools that drive analytical insights from data.

The investment from HgCapital will enable Evaluate to reinforce its growth position, enabling the Company to grow its customer base and support its strategy to expand the intelligence and forecasts it provides to its customers.

Jonathan de Pass, Founder and Chairman of Evaluate, said: “We have established a longstanding relationship with Quayle Munro and they proved to be an excellent partner to represent us on this transaction. Their understanding of our business, combined with their experience and relationships in private equity, played an important role in identifying the right investor to take Evaluate forward. The team managed the process effectively and provided robust, independent advice at every stage, achieving an excellent outcome for the shareholders.”

David Issott, Director in the Mercury Team, said: “Evaluate was the first company of its kind to offer such specialist intelligence services and since its inception, has had a track record of consistent growth. Our investment in Evaluate represents the Mercury team’s approach to investing into technology infrastructure businesses that occupy growing niches. We have great confidence in the team and the business.”

Key Transactions

Contact Us

Craig  Muir Craig Muir Find out more